European Neuropsychopharmacology最新文献

筛选
英文 中文
Redefining schizophrenia treatment with muscarinic modulation—A perspective 用毒蕈碱调节重新定义精神分裂症治疗——一个视角。
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-12-05 DOI: 10.1016/j.euroneuro.2024.11.014
Muhammad Furqan
{"title":"Redefining schizophrenia treatment with muscarinic modulation—A perspective","authors":"Muhammad Furqan","doi":"10.1016/j.euroneuro.2024.11.014","DOIUrl":"10.1016/j.euroneuro.2024.11.014","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"92 ","pages":"Pages 19-20"},"PeriodicalIF":6.1,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of mortality and complications in people with depressive disorder and diabetes mellitus: A 20-year population-based propensity score-matched cohort study 抑郁症和糖尿病患者的死亡率和并发症风险:一项20年基于人群的倾向评分匹配队列研究
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-30 DOI: 10.1016/j.euroneuro.2024.11.011
Matthew Tsz Ho Ho , Joe Kwun Nam Chan , Heidi Ka Ying Lo , Catherine Zhiqian Fang , Corine Sau Man Wong , Krystal Chi Kei Lee , Francisco Tsz Tsun Lai , Amy Pui Pui Ng , Ken Qingqi Chen , William Chi Wai Wong , Wing Chung Chang
{"title":"Risk of mortality and complications in people with depressive disorder and diabetes mellitus: A 20-year population-based propensity score-matched cohort study","authors":"Matthew Tsz Ho Ho ,&nbsp;Joe Kwun Nam Chan ,&nbsp;Heidi Ka Ying Lo ,&nbsp;Catherine Zhiqian Fang ,&nbsp;Corine Sau Man Wong ,&nbsp;Krystal Chi Kei Lee ,&nbsp;Francisco Tsz Tsun Lai ,&nbsp;Amy Pui Pui Ng ,&nbsp;Ken Qingqi Chen ,&nbsp;William Chi Wai Wong ,&nbsp;Wing Chung Chang","doi":"10.1016/j.euroneuro.2024.11.011","DOIUrl":"10.1016/j.euroneuro.2024.11.011","url":null,"abstract":"<div><div>People with depression have increased premature mortality and elevated prevalence of diabetes-mellitus compared to general population. However, risk of mortality and diabetes-related complications among patients with depression and co-occurring diabetes is under-studied. This population-based propensity score-matched (1:10) cohort study identified 12,175 patients with pre-existing depression and incident-diabetes (depression-diabetes group) and 117,958 patients with incident-diabetes only (diabetes-only group) between 2002 and 2021 in Hong-Kong, using territory-wide medical-record database of public-healthcare services, to investigate whether depression increased the risk of overall mortality, complications and post-complication mortality in people with diabetes. Associations of depression with all-cause mortality, complication and post-complication all-cause mortality rates were examined by Cox proportional-hazards model. Complications were assessed by Diabetes-Complications-Severity-Index (DCSI). Associations of complications, in terms of DCSI scores (complication burden), specific types and two-way combinations of complications (complication patterns) with all-cause mortality rate in depression were also examined. Our results showed that depression-diabetes group exhibited increased all-cause mortality risk (adjusted hazards-ratio: 1.06 [95 %CI: 1.02–1.10]) relative to diabetes-only group, particularly among men and older age group, with significantly higher rate of experiencing neuropathy (1.44 [1.27–1.62]) and metabolic complications (1.30 [1.09–1.56]) and lower likelihood of peripheral-vascular complications, retinopathy and nephropathy, albeit comparable macrovascular and microvascular complication rates. The mortality-rate-ratio for patients with depression and diabetes was significantly higher than patients with diabetes-only at a low level of complication burden. In conclusion, depression patients with co-occurring diabetes are at increased risk of excess mortality. Further research is warranted to improve diabetes-related outcomes and reduce mortality gap in this vulnerable population.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"92 ","pages":"Pages 10-18"},"PeriodicalIF":6.1,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142745072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Amphiphysin and GAD65 IgG antibodies in patients with obsessive-compulsive syndromes 强迫综合征患者的Amphiphysin和GAD65 IgG抗体
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-30 DOI: 10.1016/j.euroneuro.2024.10.005
Katharina von Zedtwitz , Bernd Feige , Alexander Maier , Sarah L. Schaefer , Kathrin Nickel , Marco Reisert , Kai Spiegelhalder , Nils Venhoff , Joachim Brumberg , Horst Urbach , Rick Dersch , Miriam A. Schiele , Katharina Domschke , Ludger Tebartz van Elst , Volker A. Coenen , Luciana Hannibal , Harald Prüss , Simon J. Maier , Dominique Endres
{"title":"Amphiphysin and GAD65 IgG antibodies in patients with obsessive-compulsive syndromes","authors":"Katharina von Zedtwitz ,&nbsp;Bernd Feige ,&nbsp;Alexander Maier ,&nbsp;Sarah L. Schaefer ,&nbsp;Kathrin Nickel ,&nbsp;Marco Reisert ,&nbsp;Kai Spiegelhalder ,&nbsp;Nils Venhoff ,&nbsp;Joachim Brumberg ,&nbsp;Horst Urbach ,&nbsp;Rick Dersch ,&nbsp;Miriam A. Schiele ,&nbsp;Katharina Domschke ,&nbsp;Ludger Tebartz van Elst ,&nbsp;Volker A. Coenen ,&nbsp;Luciana Hannibal ,&nbsp;Harald Prüss ,&nbsp;Simon J. Maier ,&nbsp;Dominique Endres","doi":"10.1016/j.euroneuro.2024.10.005","DOIUrl":"10.1016/j.euroneuro.2024.10.005","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"90 ","pages":"Pages 80-82"},"PeriodicalIF":6.1,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between genetic risk of attention deficit hyperactivity disorder and trajectories of daily gaming time in children 儿童注意缺陷多动障碍遗传风险与每日游戏时间轨迹的关系
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-29 DOI: 10.1016/j.euroneuro.2024.11.012
Nagahide Takahashi , Akemi Okumura , Tomoko Nishimura , Taeko Harada , Toshiki Iwabuchi , Md Shafiur Rahman , Kenji J. Tsuchiya
{"title":"Association between genetic risk of attention deficit hyperactivity disorder and trajectories of daily gaming time in children","authors":"Nagahide Takahashi ,&nbsp;Akemi Okumura ,&nbsp;Tomoko Nishimura ,&nbsp;Taeko Harada ,&nbsp;Toshiki Iwabuchi ,&nbsp;Md Shafiur Rahman ,&nbsp;Kenji J. Tsuchiya","doi":"10.1016/j.euroneuro.2024.11.012","DOIUrl":"10.1016/j.euroneuro.2024.11.012","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 54-55"},"PeriodicalIF":6.1,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of mortality and complications in patients with severe mental illness and co-occurring diabetes mellitus: A systematic review and meta-analysis 严重精神疾病和并发糖尿病患者的死亡和并发症风险:系统回顾和荟萃分析
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-28 DOI: 10.1016/j.euroneuro.2024.11.002
Matthew Tsz Ho Ho , Joe Kwun Nam Chan , Will Chi Yuen Chiu , Lucy Lo Wah Tsang , Kenneth Shut Wah Chan , Mimi Mei Cheung Wong , Ho Hon Wong , Pui Fai Pang , Wing Chung Chang
{"title":"Risk of mortality and complications in patients with severe mental illness and co-occurring diabetes mellitus: A systematic review and meta-analysis","authors":"Matthew Tsz Ho Ho ,&nbsp;Joe Kwun Nam Chan ,&nbsp;Will Chi Yuen Chiu ,&nbsp;Lucy Lo Wah Tsang ,&nbsp;Kenneth Shut Wah Chan ,&nbsp;Mimi Mei Cheung Wong ,&nbsp;Ho Hon Wong ,&nbsp;Pui Fai Pang ,&nbsp;Wing Chung Chang","doi":"10.1016/j.euroneuro.2024.11.002","DOIUrl":"10.1016/j.euroneuro.2024.11.002","url":null,"abstract":"<div><div>People with severe-mental-illness (SMI), often defined as “schizophrenia-spectrum disorders and bipolar disorder”, have increased premature mortality and elevated prevalence of diabetes compared with general population. Evidence indicated that one-third of their premature death was from cardiovascular diseases (CVD), with risk conferred by diabetes. Although earlier studies have examined SMI-associated diabetes-related outcomes, findings were inconsistent and not systematically evaluated. We systematically reviewed and quantitatively synthesized diabetes-related outcomes in patients with SMI (schizophrenia-spectrum disorders and bipolar disorder) by searching Embase, MEDLINE, PsycInfo, and Web-of-Science from inception to 31-March-2024, and included studies examining mortality and complication outcomes in SMI patients with co-occurring diabetes relative to patients with diabetes-only. Results were synthesized by random-effects models, with stratified-analyses by study-level characteristics. The study was registered with PROSPERO (CRD42023448490). Twenty-one studies involving 161,156 SMI patients with co-occurring diabetes were identified from ten regions. Regarding mortality risk, SMI-diabetes group exhibited increased risks of all-cause mortality (RR=1.77[95 % CI: 1.46–2.14]) and CVD-specific mortality (1.88[1.73–2.04]) relative to diabetes-only group. All-cause mortality risk was present in distinct regions and has persisted over time. Regarding complication risk, SMI-diabetes group showed higher risk of any complications (1.23[1.06–1.43]) than comparison, with stratified-analyses showing higher risk of metabolic-complications (1.84[1.58–2.15]), and lower likelihood of peripheral-vascular complications (0.91[0.84–0.99]), neuropathy (0.85[0.78–0.93]), and retinopathy (0.70[0.60–0.82]), albeit comparable cardiovascular-complications (1.04[0.89–1.22]), cerebrovascular-complications (1.07[0.86–1.33]), and nephropathy (0.92[0.72–1.17]). High heterogeneity was noted and could not be fully-explained by subgroup-analyses. Implementation of targeted interventions is needed to rectify their diabetes-related outcomes and mortality gap.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 25-36"},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142722854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitochondrial DNA copy number is significantly increased in bipolar disorder patients and is correlated with long-term lithium treatment 双相情感障碍患者线粒体DNA拷贝数显著增加,且与长期锂治疗相关
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-28 DOI: 10.1016/j.euroneuro.2024.10.012
Anna Meloni , Pasquale Paribello , Marco Pinna , Martina Contu , Raffaella Ardau , Caterina Chillotti , Donatella Congiu , Massimo Gennerelli , Alessandra Minelli , Lisa Buson , Giovanni Severino , Claudia Pisanu , Mirko Manchia , Alessio Squassina
{"title":"Mitochondrial DNA copy number is significantly increased in bipolar disorder patients and is correlated with long-term lithium treatment","authors":"Anna Meloni ,&nbsp;Pasquale Paribello ,&nbsp;Marco Pinna ,&nbsp;Martina Contu ,&nbsp;Raffaella Ardau ,&nbsp;Caterina Chillotti ,&nbsp;Donatella Congiu ,&nbsp;Massimo Gennerelli ,&nbsp;Alessandra Minelli ,&nbsp;Lisa Buson ,&nbsp;Giovanni Severino ,&nbsp;Claudia Pisanu ,&nbsp;Mirko Manchia ,&nbsp;Alessio Squassina","doi":"10.1016/j.euroneuro.2024.10.012","DOIUrl":"10.1016/j.euroneuro.2024.10.012","url":null,"abstract":"<div><div>Mitochondrial dysfunctions have been reported in bipolar disorder (BD), but their role in the etiopathogenesis of BD as well as their implications in modulating response to pharmacological treatments with psychotropic medications have been scarcely explored. Mitochondrial DNA copy number (mtDNA-cn) has been linked to mitochondria functioning, and, despite some degree of inconsistence, previous findings showed that BD patients present significant differences in mtDNA-cn compared to healthy controls. Here we measured mtDNA-cn in a sample of 89 patients with BD and 78 healthy controls (HC). Patients in the BD sample were treated either with lithium (<em>n</em> = 47) and characterized as responders (<em>n</em> = 22) or non-responders (<em>n</em> = 25), or with other mood stabilizers (<em>n</em> = 42). BD patients had larger mtDNA-cn compared to HC (adjusted model: F<sub>2</sub>=9.832; <em>p</em> = 0.000095; contribution of diagnosis F<sub>1</sub>= 10.798; <em>p</em> = 0.001). When the BD sample was stratified for treatment exposure, mtDNA-cn was lower in patients treated with lithium compared to those treated with other mood stabilizers (adjusted model: F<sub>4</sub>=23.770, <em>p</em> = 7.0929E-13; contribution of treatment: F<sub>1</sub>=54.300, <em>p</em> = 1.55E-10). Moreover mtDNA-cn was higher in patients treated with other mood stabilizers compared to controls and Li-treated BD patients (F<sub>3</sub>=28.125, <em>p</em> = 1.36E-14; contribution of groups F<sub>2</sub>=36.156, <em>p</em> = 1.25E-13). Finally, there was no difference in mtDNA-cn levels in lithium responders compared to non-responders and neither between the two diagnostic groups (BD type 1 and 2). Our findings suggest that BD may be associated with mitochondrial dysfunctions, and that exposure to lithium but not to other mood stabilizers may restore these abnormalities, though this does not appear correlated with the clinical efficacy of lithium.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 37-44"},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cannabis use and psychosis: evidence and new clinical features of a new epidemic 大麻使用和精神病:一种新流行病的证据和新的临床特征
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-28 DOI: 10.1016/j.euroneuro.2024.11.007
Giovanni Martinotti , Marta Di Forti
{"title":"Cannabis use and psychosis: evidence and new clinical features of a new epidemic","authors":"Giovanni Martinotti ,&nbsp;Marta Di Forti","doi":"10.1016/j.euroneuro.2024.11.007","DOIUrl":"10.1016/j.euroneuro.2024.11.007","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 45-46"},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing differential diagnostics and identifying transdiagnostic treatment targets using virtual reality 利用虚拟现实优化鉴别诊断和识别跨诊断治疗目标
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-28 DOI: 10.1016/j.euroneuro.2024.11.006
Hanne Lie Kjærstad , Andreas Elleby Jespersen , Johanne Lilmose Bech , Sofie Weidemann , Anne Juul Bjertrup , Emilie Hestbæk Jacobsen , Sebastian Simonsen , Louise Birkedal Glenthøj , Merete Nordentoft , Kristian Reveles , Tine Wøbbe , Mads Lopes , Daniel Lyngholm , Kamilla Woznica Miskowiak
{"title":"Optimizing differential diagnostics and identifying transdiagnostic treatment targets using virtual reality","authors":"Hanne Lie Kjærstad ,&nbsp;Andreas Elleby Jespersen ,&nbsp;Johanne Lilmose Bech ,&nbsp;Sofie Weidemann ,&nbsp;Anne Juul Bjertrup ,&nbsp;Emilie Hestbæk Jacobsen ,&nbsp;Sebastian Simonsen ,&nbsp;Louise Birkedal Glenthøj ,&nbsp;Merete Nordentoft ,&nbsp;Kristian Reveles ,&nbsp;Tine Wøbbe ,&nbsp;Mads Lopes ,&nbsp;Daniel Lyngholm ,&nbsp;Kamilla Woznica Miskowiak","doi":"10.1016/j.euroneuro.2024.11.006","DOIUrl":"10.1016/j.euroneuro.2024.11.006","url":null,"abstract":"<div><div>Accurate diagnosis in psychiatry remains a significant challenge, often delaying appropriate treatment and resulting in poorer clinical outcomes. Identifying precise biomarkers for differential diagnosis is therefore crucial. This study aimed to identify distinct behavioral and psychophysiological markers of emotional reactivity in virtual reality (VR) settings among individuals with bipolar disorder (BD), borderline personality disorder (BPD), schizophrenia spectrum disorders (SSD), and healthy controls (HC). Participants (BD: <em>n</em> = 32, BPD: <em>n</em> = 21, SSD: <em>n</em> = 17, HC: <em>n</em> = 30) aged 19–60 were exposed to six immersive 360-degree social VR scenarios, ranging from neutral to highly emotional contexts (e.g., an elevator ride, a crying baby). Emotional responses were self-rated on a 1–5 scale, while galvanic skin response (GSR) was continuously recorded. Scenarios assessed feelings of unpleasantness, pleasantness, being observed, and the urge to comfort. Across diagnoses, individuals with mental health conditions reported more negative emotional responses (greater unpleasantness) across both neutral and negative scenarios (<em>p</em>s ≤ 0.02) despite similar GSR levels to HC. Specifically, in the elevator scenario, BPD and SSD experienced greater unpleasantness and feelings of being observed, coupled with stronger GSRs compared to BD (<em>p</em>s ≤ 0.03). SSD reported higher unpleasantness in the canteen scenario, less pleasantness in the happy baby scenario, and overall higher GSR than BD (<em>p</em>s ≤ 0.049). Negative emotional reactivity was consistent across BD, BPD, and SSD, with heightened emotional and physiological responses distinguishing SSD and BPD from BD in specific VR contexts. VR-based assessments of emotional and physiological markers show promise for improving differential diagnosis and identifying transdiagnostic treatment targets.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"92 ","pages":"Pages 1-9"},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142745071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rare Genetic variation in schizophrenia: Are the most obvious ‘druggable pathways’ hiding in plain sight? 精神分裂症的罕见遗传变异:最明显的“可药物途径”是否隐藏在人们的视线中?
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-28 DOI: 10.1016/j.euroneuro.2024.11.010
Mark Ainsley Colijn
{"title":"Rare Genetic variation in schizophrenia: Are the most obvious ‘druggable pathways’ hiding in plain sight?","authors":"Mark Ainsley Colijn","doi":"10.1016/j.euroneuro.2024.11.010","DOIUrl":"10.1016/j.euroneuro.2024.11.010","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 52-53"},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Valproate's impact on future generations — A call for stricter guidelines for maternal and paternal use 丙戊酸对后代的影响——呼吁对母亲和父亲的使用制定更严格的指导方针
IF 6.1 2区 医学
European Neuropsychopharmacology Pub Date : 2024-11-28 DOI: 10.1016/j.euroneuro.2024.11.005
Meritxell González-Campos , Helena Andreu , Oscar De Juan , Luis Olivier , Gerard Anmella
{"title":"Valproate's impact on future generations — A call for stricter guidelines for maternal and paternal use","authors":"Meritxell González-Campos ,&nbsp;Helena Andreu ,&nbsp;Oscar De Juan ,&nbsp;Luis Olivier ,&nbsp;Gerard Anmella","doi":"10.1016/j.euroneuro.2024.11.005","DOIUrl":"10.1016/j.euroneuro.2024.11.005","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 50-51"},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信